RxDoctor Payments Data

Carrie Connett, DO

Family Medicine · Murrells Inlet, SCNPI 1831166297

Payments from drug & device makers

$7,729in general payments, 2019–2025

Across 640 payments — averaging $12.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Johnson & Johnson$634
  • Merck$611
  • AstraZeneca$553
  • GSK$379
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$7,724100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,729 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$136,609
Medicare patients
386
Services billed
1,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin43$58,432
MounjaroTirzepatide48$54,504
EliquisApixaban44$48,378
JanuviaSitagliptin Phosphate39$40,561
OzempicSemaglutide31$33,782
Breo ElliptaFluticasone/Vilanterol34$24,786
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$24,434
Tresiba Flextouch U-200Insulin Degludec17$16,582
XareltoRivaroxaban12$16,295
Tresiba Flextouch U-100Insulin Degludec17$10,033
SynthroidLevothyroxine Sodium57$4,194
Duloxetine Hcl133$4,027
Levothyroxine Sodium313$3,582
Atorvastatin Calcium328$3,386
Trazodone Hcl165$2,854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$155$58,43243 claims
Lilly USA, LLCMounjaro$356$54,50448 claims
GSKBreo Ellipta, Trelegy Ellipta$379$49,22063 claims
PfizerEliquis$359$48,37844 claims
MerckJanuvia$611$40,56139 claims
Novo NordiskOzempic$1,020$33,78231 claims
Johnson & JohnsonXarelto$634$16,29512 claims
AbbVieSynthroid$1,303$4,19457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Murrells Inlet

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →